Waldencast Stock News

Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical Co., Ltd. (“Rohto”) for USD $82.5 million.

First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025 First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025

A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair* A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair*

U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market

Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand's Addressable Market in the U.S.

Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaesti...

Waldencast is a fast-growing beauty company with strong brands (Milk Makeup, Obagi), but faces margin pressure and negative earnings due to high SG&A and debt. Recent revenue growth remains solid, but Q1 FY25 saw a sales dip, especially in Milk Makeup, due to international headwinds and inventory adjustments. The company's financials are typical for a high-growth firm: negative cash flow, high ...